Ovid Therapeutics Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

OVID$2.850.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)	March 31,2026	December 31,2025
Assets
Current assets:
Cash and cash equivalents	$94,064	$13,153
Marketable securities	61,458	56,482
Prepaid expenses and other current assets	4,623	4,733
Total current assets	160,145	74,368
Marketable securities - noncurrent	10,076	20,812
Long-term equity investments	41,961	41,961
Restricted cash	1,931	1,931
Right-of-use asset, net	11,298	11,610
Property and equipment, net	217	252
Total assets	$225,628	$150,934
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$8,876	$1,956
Accrued expenses	5,413	4,899
Current portion, lease liability	1,459	1,433
Total current liabilities	15,748	8,288
Long-term liabilities:
Lease liability	11,611	11,986
Total liabilities	27,359	20,274
Stockholders’ equity:
Common stock, $0.001 par value; 315,000,000 shares authorized; 167,266,466 and 130,184,353 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	167	130
Additional paid-in-capital	537,225	452,445
Accumulated other comprehensive loss	(422)	(202)
Accumulated deficit	(338,701)	(321,713)
Total stockholders’ equity	198,269	130,660
Total liabilities and stockholders’ equity	$225,628	$150,934

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.